PDF(Pubmed)
Abstract：
UNASSIGNED: The genetic diversity of Mycobacterium tuberculosis complex (MTBC) strains was characterized among isolates from individuals with pulmonary tuberculosis (PTB) symptoms attended holy water sites (HWSs) in the Amhara region, Ethiopia.
UNASSIGNED: A cross-sectional study was done from June 2019 to March 2020 to describe the genetic diversity and drug-resistance profiles of MTBC isolates. Sputum specimens were collected and cultured in the Löwenstein-Jensen culture medium. Line Probe Assay, MTBDRplus VER 2.0, and MTBDRsl VER 2.0 were used to detect first-and second-line anti-TB drug-resistance patterns. A spoligotyping technique was utilized to characterize the genetic diversity. Statistical analysis was performed using STATA 15.
UNASSIGNED: Of 560 PTB-symptomatic participants, 122 (21.8%) were culture-positive cases. Spoligotyping of 116 isolates revealed diverse MTBC sublineages, with four major lineages: Euro-American (EA) (Lineage 4), East-African-Indian (EAI) (Lineage 3), Ethiopian (ETH) (Lineage 7), East Asian (EA) (Lineage 2). The majority (96.6%) of the isolates were EA (lineage 4) and EAI, with proportions of 54.3% and 42.2%, respectively. A total of 31 spoligotype patterns were identified, 26 of which were documented in the SITVIT2 database. Of these, there were 15 unique spoligotypes, while eleven were grouped with 2-17 isolates. SIT149/T3-ETH (n = 17), SIT26/CAS1-DELHI (n = 16), SIT25/CAS1-DELHI (n = 12), and SIT52/T2 (n = 11) spoligotypes were predominant. A rare spoligotype pattern: SIT41/Turkey and SIT1/Beijing, has also been identified in North Shewa. The overall clustering rate of sub-lineages with known SIT was 76.4%.Of the 122 culture-positive isolates tested, 16.4% were resistant to rifampicin (RIF) and/or isoniazid (INH). Multidrug-resistant TB (MDR-TB) was detected in 12.3% of isolates, five of which were fluoroquinolones (FLQs) resistant. SIT149/T3-ETH and SIT21/CAS1-KILI sublineages showed a higher proportion of drug resistance.
UNASSIGNED: Diverse MTBC spoligotypes were identified, with the T and CAS families and EA (lineage 4) predominating. A high prevalence of drug-resistant TB, with SIT149/T3-ETH and CAS1-KILI sublineages comprising a greater share, was observed. A study with large sample size and a sequencing method with stronger discriminatory power is warranted to understand better the genetic diversity of circulating MTBC in this cohort of study, which would help to adopt targeted interventions.
UNASSIGNED: A cross-sectional study was done from June 2019 to March 2020 to describe the genetic diversity and drug-resistance profiles of MTBC isolates. Sputum specimens were collected and cultured in the Löwenstein-Jensen culture medium. Line Probe Assay, MTBDRplus VER 2.0, and MTBDRsl VER 2.0 were used to detect first-and second-line anti-TB drug-resistance patterns. A spoligotyping technique was utilized to characterize the genetic diversity. Statistical analysis was performed using STATA 15.
UNASSIGNED: Of 560 PTB-symptomatic participants, 122 (21.8%) were culture-positive cases. Spoligotyping of 116 isolates revealed diverse MTBC sublineages, with four major lineages: Euro-American (EA) (Lineage 4), East-African-Indian (EAI) (Lineage 3), Ethiopian (ETH) (Lineage 7), East Asian (EA) (Lineage 2). The majority (96.6%) of the isolates were EA (lineage 4) and EAI, with proportions of 54.3% and 42.2%, respectively. A total of 31 spoligotype patterns were identified, 26 of which were documented in the SITVIT2 database. Of these, there were 15 unique spoligotypes, while eleven were grouped with 2-17 isolates. SIT149/T3-ETH (n = 17), SIT26/CAS1-DELHI (n = 16), SIT25/CAS1-DELHI (n = 12), and SIT52/T2 (n = 11) spoligotypes were predominant. A rare spoligotype pattern: SIT41/Turkey and SIT1/Beijing, has also been identified in North Shewa. The overall clustering rate of sub-lineages with known SIT was 76.4%.Of the 122 culture-positive isolates tested, 16.4% were resistant to rifampicin (RIF) and/or isoniazid (INH). Multidrug-resistant TB (MDR-TB) was detected in 12.3% of isolates, five of which were fluoroquinolones (FLQs) resistant. SIT149/T3-ETH and SIT21/CAS1-KILI sublineages showed a higher proportion of drug resistance.
UNASSIGNED: Diverse MTBC spoligotypes were identified, with the T and CAS families and EA (lineage 4) predominating. A high prevalence of drug-resistant TB, with SIT149/T3-ETH and CAS1-KILI sublineages comprising a greater share, was observed. A study with large sample size and a sequencing method with stronger discriminatory power is warranted to understand better the genetic diversity of circulating MTBC in this cohort of study, which would help to adopt targeted interventions.
摘要：
■结核分枝杆菌复合体（MTBC）菌株的遗传多样性在Amhara地区的圣水场所（HWS）出现肺结核（PTB）症状的个体中进行了表征，埃塞俄比亚。
■从2019年6月至2020年3月进行了一项横断面研究，以描述MTBC分离株的遗传多样性和耐药性。收集痰标本并在Löwenstein-Jensen培养基中培养。线探针测定,MTBDRplusVER2.0和MTBDRslVER2.0用于检测一线和二线抗TB药物抗性模式。利用spoligotyping技术来表征遗传多样性。使用STATA15进行统计分析。
■在560名有PTB症状的参与者中，122例(21.8%)为培养阳性病例。116个分离株的Spoligotyping揭示了不同的MTBC亚谱系，有四个主要谱系：欧美（EA）（谱系4），东非印第安人（EAI）（谱系3），埃塞俄比亚（ETH）（谱系7），东亚（EA）（谱系2）。大多数(96.6%)的分离株是EA(谱系4)和EAI，比例分别为54.3%和42.2%，分别。总共确定了31种spoligotype模式，其中26个记录在SITVIT2数据库中。其中,有15种独特的spoligotypes,而11个被分组为2-17个分离株。SIT149/T3-ETH（n=17），SIT26/CAS1-DELHI（n=16），SIT25/CAS1-DELHI（n=12），以SIT52/T2（n=11）为主。一种罕见的spoligotype模式：SIT41/土耳其和SIT1/北京，在北谢瓦也被确认。具有已知SIT的子谱系的总体聚类率为76.4%。在测试的122株培养阳性菌株中，16.4%对利福平(RIF)和/或异烟肼(异烟肼)耐药。在12.3％的分离株中检测到耐多药结核病（MDR-TB），其中五种是氟喹诺酮类药物（FLQs）耐药。SIT149/T3-ETH和SIT21/CAS1-KILI亚谱系显示较高比例的耐药性。
■确定了不同的MTBCspoligotypes，以T和CAS家族和EA（谱系4）为主。耐药结核病的高流行率，SIT149/T3-ETH和CAS1-KILI子谱系占更大份额，被观察到。在本研究队列中，有必要进行大样本量和具有更强鉴别力的测序方法的研究，以更好地了解循环MTBC的遗传多样性。这将有助于采取有针对性的干预措施。
■从2019年6月至2020年3月进行了一项横断面研究，以描述MTBC分离株的遗传多样性和耐药性。收集痰标本并在Löwenstein-Jensen培养基中培养。线探针测定,MTBDRplusVER2.0和MTBDRslVER2.0用于检测一线和二线抗TB药物抗性模式。利用spoligotyping技术来表征遗传多样性。使用STATA15进行统计分析。
■在560名有PTB症状的参与者中，122例(21.8%)为培养阳性病例。116个分离株的Spoligotyping揭示了不同的MTBC亚谱系，有四个主要谱系：欧美（EA）（谱系4），东非印第安人（EAI）（谱系3），埃塞俄比亚（ETH）（谱系7），东亚（EA）（谱系2）。大多数(96.6%)的分离株是EA(谱系4)和EAI，比例分别为54.3%和42.2%，分别。总共确定了31种spoligotype模式，其中26个记录在SITVIT2数据库中。其中,有15种独特的spoligotypes,而11个被分组为2-17个分离株。SIT149/T3-ETH（n=17），SIT26/CAS1-DELHI（n=16），SIT25/CAS1-DELHI（n=12），以SIT52/T2（n=11）为主。一种罕见的spoligotype模式：SIT41/土耳其和SIT1/北京，在北谢瓦也被确认。具有已知SIT的子谱系的总体聚类率为76.4%。在测试的122株培养阳性菌株中，16.4%对利福平(RIF)和/或异烟肼(异烟肼)耐药。在12.3％的分离株中检测到耐多药结核病（MDR-TB），其中五种是氟喹诺酮类药物（FLQs）耐药。SIT149/T3-ETH和SIT21/CAS1-KILI亚谱系显示较高比例的耐药性。
■确定了不同的MTBCspoligotypes，以T和CAS家族和EA（谱系4）为主。耐药结核病的高流行率，SIT149/T3-ETH和CAS1-KILI子谱系占更大份额，被观察到。在本研究队列中，有必要进行大样本量和具有更强鉴别力的测序方法的研究，以更好地了解循环MTBC的遗传多样性。这将有助于采取有针对性的干预措施。
